PL387780A1 - Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, zastosowanie wektorowej cząsteczki wirusopodobnej oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną - Google Patents

Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, zastosowanie wektorowej cząsteczki wirusopodobnej oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną

Info

Publication number
PL387780A1
PL387780A1 PL387780A PL38778009A PL387780A1 PL 387780 A1 PL387780 A1 PL 387780A1 PL 387780 A PL387780 A PL 387780A PL 38778009 A PL38778009 A PL 38778009A PL 387780 A1 PL387780 A1 PL 387780A1
Authority
PL
Poland
Prior art keywords
virus
vector particle
vector
particle
production
Prior art date
Application number
PL387780A
Other languages
English (en)
Other versions
PL222496B1 (pl
Inventor
Ewa Szołajska
Jadwiga Chroboczek
Monika Żochowska
Original Assignee
Instytut Biochemii I Biofizyki Pan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biochemii I Biofizyki Pan filed Critical Instytut Biochemii I Biofizyki Pan
Priority to PL387780A priority Critical patent/PL222496B1/pl
Priority to EP10726635.5A priority patent/EP2437787B1/en
Priority to PCT/PL2010/000026 priority patent/WO2010117287A2/en
Priority to BRPI1016056A priority patent/BRPI1016056A2/pt
Priority to US13/263,632 priority patent/US8765666B2/en
Priority to JP2012504645A priority patent/JP5841045B2/ja
Publication of PL387780A1 publication Critical patent/PL387780A1/pl
Priority to JP2015179964A priority patent/JP2016053026A/ja
Publication of PL222496B1 publication Critical patent/PL222496B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

Przedmiotem wynalazku jest wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, zastosowanie wektorowej cząsteczki wirusopodobnej oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną. Wektor ten jest przeznaczony do wprowadzania do specyficznych tkanek ssaczych czynników terapeutycznych, zwłaszcza niskocząsteczkowych leków, szczególnie niskocząsteczkowych leków antynowotworowych do tkanek rakowych. Bardziej szczegółowo wynalazek dotyczy wektorowej cząsteczki wirusopodobnej, stanowiącej dodekahedron adenowirusowy z przyłączoną kowalencyjnie substancją terapeutyczną.
PL387780A 2009-04-10 2009-04-10 Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną PL222496B1 (pl)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PL387780A PL222496B1 (pl) 2009-04-10 2009-04-10 Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną
EP10726635.5A EP2437787B1 (en) 2009-04-10 2010-04-09 A virus-like particle vector for delivery of pharmaceutical agents, a process for the manufacture thereof, its uses and a pharmaceutical composition.
PCT/PL2010/000026 WO2010117287A2 (en) 2009-04-10 2010-04-09 A virus-like particle vector for delivery of pharmaceutical agents, a process for the manufacture thereof, its uses and a pharmaceutical composition.
BRPI1016056A BRPI1016056A2 (pt) 2009-04-10 2010-04-09 vetor de partícula similar á virus para distribuição de agentes farmacêuticos, um processo para a produção deste, seus usos e uma composição farmacêutica
US13/263,632 US8765666B2 (en) 2009-04-10 2010-04-09 Adenovirus dodecahedron particles for delivery of pharmaceutical agents
JP2012504645A JP5841045B2 (ja) 2009-04-10 2010-04-09 医薬品送達用のウイルス様粒子ベクター、その製造方法、使用、及び医薬組成物
JP2015179964A JP2016053026A (ja) 2009-04-10 2015-09-11 医薬品送達用のウイルス様粒子ベクター、その製造方法、使用、及び医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL387780A PL222496B1 (pl) 2009-04-10 2009-04-10 Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną

Publications (2)

Publication Number Publication Date
PL387780A1 true PL387780A1 (pl) 2010-10-11
PL222496B1 PL222496B1 (pl) 2016-08-31

Family

ID=42752950

Family Applications (1)

Application Number Title Priority Date Filing Date
PL387780A PL222496B1 (pl) 2009-04-10 2009-04-10 Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną

Country Status (6)

Country Link
US (1) US8765666B2 (pl)
EP (1) EP2437787B1 (pl)
JP (2) JP5841045B2 (pl)
BR (1) BRPI1016056A2 (pl)
PL (1) PL222496B1 (pl)
WO (1) WO2010117287A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014212722A (ja) * 2013-04-24 2014-11-17 学校法人加計学園 八面体構造を有するｂ型肝炎ウイルス様粒子結晶
US10316295B2 (en) 2015-12-17 2019-06-11 The Penn State Research Foundation Paramyxovirus virus-like particles as protein delivery vehicles
US12600956B2 (en) 2015-12-17 2026-04-14 The Penn State Research Foundation Paramyxovirus virus-like particles as protein delivery vehicles
JP7466271B2 (ja) 2016-03-31 2024-04-12 ザ ヨーロピアン モレキュラー バイオロジー ラボラトリー アデノウイルスコートタンパク質由来送達賦形剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69634489T2 (de) * 1995-11-13 2006-02-16 Commissariat à l'Energie Atomique Adenovirus dodekahedrischer proteinkomplex, dieser enthaltende zusammensetzung und verwendungen davon
FR2747681B1 (fr) * 1996-04-18 1998-06-19 Commissariat Energie Atomique Complexe proteique dodecaedrique adenoviral, composition le contenant et ses applications
FR2741087B1 (fr) * 1995-11-13 1998-01-09 Commissariat Energie Atomique Complexe proteique dodecaedrique adenoviral, procede de preparation, composition le contenant et ses applications
CA2487849A1 (en) * 2002-07-18 2004-01-29 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
ATE441429T1 (de) * 2002-07-19 2009-09-15 Cytos Biotechnology Ag Ghrelin-träger-konjugate
CA2501701A1 (en) * 2002-11-01 2004-05-13 Genomidea Inc. Chemotherapeutic agent-incorporated pharmaceutical preparation
US7871765B2 (en) * 2004-03-31 2011-01-18 Genomidea Inc. Composition having antitumor effect
WO2007016864A1 (fr) * 2005-08-08 2007-02-15 Xun Hu Utilisation de fructus schisandrae et d'extraits de cette substance dans le but de prevenir et d'attenuer les effets toxiques et secondaires de medicaments anti-neoplasiques
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
NZ566971A (en) * 2005-09-28 2011-06-30 Cytos Biotechnology Ag Vaccine containing a virus like particle linked with an interleukin-1 molecule

Also Published As

Publication number Publication date
JP2016053026A (ja) 2016-04-14
EP2437787B1 (en) 2019-08-28
WO2010117287A3 (en) 2011-06-30
JP5841045B2 (ja) 2016-01-06
US8765666B2 (en) 2014-07-01
WO2010117287A2 (en) 2010-10-14
EP2437787A2 (en) 2012-04-11
JP2012523411A (ja) 2012-10-04
BRPI1016056A2 (pt) 2016-05-10
PL222496B1 (pl) 2016-08-31
US20120141425A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
CY1123649T1 (el) Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
CO2017001921A2 (es) Anticuerpos anti-cll-1 e inmunoconjugados
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
WO2011130753A3 (en) Functionalized nano- and micro-materials for medical therapies
IN2012DN06720A (pl)
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
BR212016030926U2 (pt) conjugados de alvo e partículas e formulações dos mesmos
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
EA201370018A1 (ru) Составы рифаксимина и их применение
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
BR112012026801B8 (pt) conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento
BR112019024747A2 (pt) formulações de dose fixa
MX2015008503A (es) Conjugados dirigidos encapsulados en particulas y sus formulaciones.
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
MY162146A (en) Pharmaceutical composition
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
NZ606768A (en) Pharmaceutical compositions and methods of treatment
MX2012013274A (es) Novedosos derivados de la pirimidina.
CY1119184T1 (el) Κυκλικες ν,ν’-διαρυλοθειουριες και ν,ν’-διαρυλουριες ως ανταγωνιστες υποδοχεων ανδρογονων, αντι-καρκινικος παραγοντας, μεθοδος για παραγωγη και χρηση τους
NZ712826A (en) Novel compounds and compositions for targeting cancer stem cells
EA201190236A1 (ru) Новые производные стероидных соединений [3,2-c]пиразолов с глюкокортикоидной активностью
MX2015017202A (es) Formulacion de liberacion modificada.
PL387780A1 (pl) Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, zastosowanie wektorowej cząsteczki wirusopodobnej oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną